Vaccines for Children Program Stockpile Status National Vaccine Advisory Committee February 4, 2010 Washington, DC Lance E Rodewald, MD Director, Immunization.

Slides:



Advertisements
Similar presentations
ICT Services Suppliers Briefing Thursday, 17 September 2009.
Advertisements

Vaccines related epidemiology Programme design and policy options First EpiTrain course in Advanced Epidemiology Jurmala Latvia Hanna Nohynek.
Workgroup Three (The Orange Group) Vaccine Supply Vaccine Distribution Vaccine Financing –Key issues Barriers Needs Solutions.
Pandemic Influenza Vaccine Prioritization: Rationale and Process Pandemic Influenza Vaccine: Doses Administered and Safety Training Conference Tom Shimabukuro,
An Immunization Safety Net Without Missed Opportunities: Status of the Public Sector Billing Project National Vaccine Advisory Committee September 14,
CDC Director’s Perspective Immunization Program Managers Meeting Thomas R. Frieden, MD, MPH Director, CDC Administrator, ATSDR.
Small Projects & Tailoring Using the PPA 1:15 – 2:15 Teresa Kinley, OPHPR With Panelists: Susan Wilkin, NCCDPHP Andy Autry, NCBDDD Carol Waller, NCEH/ATSDR.
1. 2 The Public Health Agency of Canada Pandemic Influenza Preparedness: An Overview Dr. Paul Gully Deputy Chief Public Health Officer Ottawa, 19 January.
To protect the health and environment of all Kansans by promoting responsible choices. Immunization Program 2009 H1N1 Adventure Governor’s Child Health.
United States-Canada Regulatory Cooperation Council United States-Canada Regulatory Cooperation Council January 30, 2012 Washington D.C
HealthSanté CanadaCanada Influenza Prevention and Control in Canada Arlene King, MD, MHSc, FRCPC Director, Immunization and Respiratory Infections Division,
National Immunization Program Report NVAC Washington, DC  February 3-4, 2004 Stephen L. Cochi, M.D., M.P.H. Acting Director, National Immunization Program.
New Procurement & Delivery Arrangements for the Schools’ Estate Presentation to Strategic Advisory Group 18 April 2005.
A Comprehensive Policy framework for the National Immunization Programme Dr Nihal Abeysinghe, [M.B.,B.S., MSc, M.D.] Chief Epidemiologist, Ministry of.
Welcome Regional Skills Policy and Sector Skills Councils – An LSC Viewpoint 19 October Chris Minett Regional Skills Director.
Multifaceted HPV Vaccination Strategies in California Achieving the Promise Avoiding the Pitfalls Heidi M. Bauer, MD MS MPH California Department of Public.
VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.
Public Health Service Response to Influenza Vaccine Supply Problems Lance E. Rodewald, MD Immunization Services Division National Immunization Program.
Proposed Changes to Advisory Committee Processes Sara Copeland, MD Designated Federal Official Secretary’s Advisory Committee on Heritable Disorders in.
Wearing their shoes How to understand and influence Public Sector Commissioners - Find out what really makes them tick Mark Algar, Owner 60sticks Ltd.
THE NATIONAL INFLUENZA VACCINE SUMMIT: UPDATE Raymond A. Strikas, M.D. Immunization Services Division National Immunization Program Coordinating Center.
Needs and Recommendations for the United States Poliovirus Vaccine Stockpile Report of the Joint Working Group of the National Vaccine Advisory Committee.
Recommendations and a Plan for Preventing Preterm Birth Secretary’s Advisory Committee on Infant Mortality (SACIM) August 10, 2015.
DRAFT V1 National Vaccine Supply Chain Innovations: Country Commitment to Ownership, Sustainability & Impact GAVI Partners’ Forum WHO – UNICEF – GAVI -
Office of Public Health Preparedness and Response Division of Strategic National Stockpile Ben Erickson Public Health Analyst Inventory Management Tracking,
Implementing New Vaccines and Vaccine Recommendations National Vaccine Advisory Committee Washington, DC September 26, 2006 Lance E. Rodewald, MD Director,
Food and Drug Administration
U.S. Pandemic Influenza Preparedness and Response: Update & Progress Report “The pandemic influenza clock is ticking. We just don’t know what time it is.”
Peter Gondo. Session overview Introduction Why monitor What to monitor How to monitor Exercise: Developing a performance monitoring plan for the FI.
Childhood Vaccine Financing: Implications for States National Vaccine Advisory Committee November 29, 2005 Washington, DC Lance E. Rodewald, MD Director,
Implementation of HPV Vaccine Claire Hannan, MPH Executive Director, AIM NVAC September 26, 2006.
America Responds: An HHS 2009-H1N1 Retrospective to Advance All Hazards Preparedness Discussion with the National Vaccine Advisory Committee June 3, 2010.
Influenza Vaccination Update for Jeanne M. Santoli, MD, MPH Deputy Director, Immunization Services Division National Center for Immunization and.
State Health Agency Perspectives on the Implementation of New Vaccines Presentation to the National Vaccine Advisory Committee September 26, 2006 Calvin.
Financing Administration of 2009 H1N1 Influenza Vaccine Megan C. Lindley, MPH National Center for Immunization and Respiratory Diseases July 27, 2009.
Polio Eradication -- Global Progress and Development of Post-Eradication Strategies: Implications for U.S. Stockpile and Outbreak Response Preparations.
July 19, 2005 Walter A. Orenstein, M.D. Professor of Medicine Director, Emory Vaccine Policy and Development Associate Director, Emory Vaccine Center Purchase.
TM OPV Stockpiling in the United States Trudy V. Murphy, M.D. National Immunization Program Centers for Disease Control and Prevention February 5, 2003.
Planning for the Influenza Season: Will it be Rain, Shine, or Hurricane? National Vaccine Advisory Committee June 7, 2005 Washington, DC Raymond.
National Vaccine Advisory Committee Report from the Chair Gus Birkhead, MD, MPH NVAC Chair February 3, 2010.
Grantee Funding Status 44 th National Immunization Conference Atlanta, GA Lance E. Rodewald, MD Director, Immunization Services Division National Center.
National Vaccine Advisory Committee A Status Report on the Pediatric Vaccine Stockpiles Pediatric Vaccine Stockpiles February 8, 2005 Eddie Wilder Project.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
1 Voluntary and Community Sector Review Voluntary & Community Sector Review Grants Strategy Working Party Participative Session 28 September 2006 Appendix.
A Vaccine Supply Update For The U.S. Market A Presentation At National Advisory Committee Meeting February 4, 2003 Dean Mason Chief, Program Support Branch.
OVERVIEW OF THE NATIONAL INFLUENZA VACCINE SUMMIT Dennis J. O’Mara Associate Director for Adult Immunization Immunization Services Division National Immunization.
VFC Pediatric Vaccine Stockpile National Vaccine Advisory Committee October 23, 2007 Gregory S. Wallace, M.D., M.S., M.P.H. Chief, Vaccine Supply and Assurance.
Country Partnership Strategy FY12-16 Consultations with Civil Society The World Bank Group June 2, 2011.
Planning for the Influenza Season National Vaccine Advisory Committee February 8, 2005 Washington, DC Lance E. Rodewald, MD Director, Immunization.
1 NVAC Washington, D.C. February 3, Agenda I.Overview of Influenza Vaccine Production and Development II.Vaccine Supply/Demand: Recent Trends.
Non-institutionalized adults vaccinated annually against influenza and ever vaccinated against pneumococcal disease. Healthy Kansans 2010 Steering Committee.
Highlights of Recent Results from the New Health Insurance Modules of the National Immunization Survey National Vaccine Advisory Committee October 22,
Public Health Options for Implementing Vaccine Recommendations: A Framework for State Decision Making Donald Williamson, M.D. National Vaccine Advisory.
Adult Immunization: Goals, Challenges, and a role for the National Vaccine Advisory Committee October 22, 2007 Raymond A. Strikas, MD National Vaccine.
CDC VACCINE STOCKPILE FISCAL AND MANAGEMENT ISSUES A Presentation At The National Vaccine Advisory Committee Meeting February 4, 2003 Kimberly S. Lane.
National Immunization Program (NIP)/Advisory Committee on Immunization Practices (ACIP) Report Stephen L. Cochi, MD, MPH Acting Director, National Immunization.
Anne Schuchat, MD Director, National Center for Immunization and Respiratory Diseases, CDC Assistant Surgeon General, US Public Health Service CVEP Symposium.
Continual Service Improvement Methods & Techniques.
1. Connecting Health Plans and Public Health to Improve Vaccine Delivery CDC Billing Project Billing Planning All-Projects’ Conference Call June 26, 2012;
A global partnership to stop measles & rubella 1 Measles & Rubella Initiative --Who We Are-- Stephen Cochi, MD, MPH Global Immunization Division Centers.
NVAC Influenza Working Group: Preliminary Report Charles Helms, M.D., Ph.D. June 1, 2004.
Influenza Vaccine Supply and Distribution: An Overview of the Season Jeanne M. Santoli, MD, MPH National Immunization Program.
Session 2: Developing a Comprehensive M&E Work Plan.
Carol Friedman, D.O. Associate Director for Adult Immunization Immunization Services Division National Center for Immunization and Respiratory Diseases.
Kindergarten Considerations and Timeline to Incorporate a New Vaccine in City and State Immunization Programs in the United States Katelyn Wells MS, Association.
ACIP Recommendations Update for the U.S. Influenza Season
Descriptive Analysis of Performance-Based Financing Education Project in Burundi Victoria Ryan World Bank Group May 16, 2017.
Emerging Gaps in Financing for New Vaccines
Dose by Dose Accountability and CAIR
Immunization in the Era of Health Reform: What’s Next?
Presentation transcript:

Vaccines for Children Program Stockpile Status National Vaccine Advisory Committee February 4, 2010 Washington, DC Lance E Rodewald, MD Director, Immunization Services Division National Center for Immunization and Respiratory Diseases, CDC

Topics  VFC Stockpile strategic plan  Next steps toward fulfilling the strategic plan  Additional planning: influenza vaccine

VFC Stockpile Strategic Plan (1)  History of VFC stockpile plan – Pre-2002 plan  Only monopoly VFC vaccines  Targets at full VFC authority – Post-2002 plan  All VFC vaccines  Targets at full VFC authority  Rationale for strategic planning – Stockpile cost was increasing rapidly with new vaccines  Characteristics of vaccines and their diseases vary and smaller target amounts may be appropriate for some vaccines  Burden of disease impact was not systematically considered in the Post-2002 plan – Development and management of stockpile was becoming more challenging due to changes in vaccines in VFC – Centralized distribution adds previously unavailable capabilities – Post-2002 plan not fully implemented, providing an opportunity to change plan prior to costly and risky build-up – Manufacturer participation is voluntary – need a plan that makes sense for all stakeholders

VFC Stockpile Strategic Plan (2)  Inputs – VFC statute – Disease / vaccine considerations  Outbreak management potential and needs  Impact of shortages on burden of disease – Vaccine use in public and private sectors  Objectives of plan – Identify the minimum target sizes of stockpile vaccines to  Meet VFC statute requirements  Meet outbreak management needs  Withstand a 1-year disruption in supply without an increase in burden of disease – Develop strategy to build to the targets over 5 years

Elements of Strategic Plan  Stockpile is a national resource – Implies loaning doses for private sector for supply maintenance  For most vaccines, a 3-month national supply (6-month federal contract supply) is the target – Smaller than previous targets  smaller “insurance policy” – MMR is exception – IPV target amount not finalized  Target amounts mirror public sector vaccine use, which is similar to private sector vaccine use  Build to new targets over 5 years and re-evaluate

Advantages of Smaller Targets  Public health benefit achievable with smaller targets is similar to that achievable with larger targets – Morbidity and mortality similar – Outbreaks able to be managed – Difference is duration of maintenance of supply in disruption  Experience managing full stockpiles will be helpful – Target amount adjustment – Physical location of stockpiled vaccine – Managing under different shortage situations  Less vaccine is at risk – ~37 M doses vs ~77 M doses – ~$1.6 B vs ~$3.5 B

Stockpile Status and Target Amounts: February 2010

Stockpile Maintenance Challenges  Introduction of new vaccines  Shelf life versus throughput balance constrains target size  Mirroring the market  Outmoded vaccines  Role of loaning doses to maintain private sector in shortage situation

Vetting and Funding Status  CDC approval January 2009  HHS vetting 2009  OMB presentation 2009 – Most funding approved for 5-year build-up – Discussions of maintenance mechanics ongoing – Further presentation to OMB policy makers 2010  Next steps – Discussions with manufacturers on key provisions – Filling to new targets over 5 years

Influenza Stockpile  Initiated after influenza season – Initially $40 M / year, all VFC funded  Contract for last doses of season – Cannot build stockpile when vaccine demand is > than supply  Use of stockpile variable, but very low – Even during sever shortage years – Funding reduced at CDC request to $7 M / year  CDC position on influenza stockpile in 2010

Conclusions  VFC enables the nation to have a public/private stockpile to maintain supply and fight outbreaks of VPDs  Prudent stockpile plan developed and now able to be implemented  Next planning step is influenza stockpile

DISCUSSION

GAO 2002; Childhood vaccines: Ensuring an adequate supply poses continuing challenges